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BACKGROUND/OBJECTIVES: The marketing authorization for the weight loss drug sibutramine was suspended in 2010 following a
major trial that showed increased rates of non-fatal myocardial infarction and cerebrovascular events in patients with pre-existing
cardiovascular disease. In routine clinical practice, sibutramine was already contraindicated in patients with cardiovascular disease
and so the relevance of these inﬂuential clinical trial ﬁndings to the ‘real World’ population of patients receiving or eligible for the
drug is questionable. We assessed rates of myocardial infarction and cerebrovascular events in a cohort of patients prescribed
sibutramine or orlistat in the United Kingdom.
SUBJECTS/METHODS: A cohort of patients prescribed weight loss medication was identiﬁed within the Clinical Practice Research
Datalink. Rates of myocardial infarction or cerebrovascular event, and all-cause mortality were compared between patients prescribed
sibutramine and similar patients prescribed orlistat, using both a multivariable Cox proportional hazard model, and propensity score-
adjusted model. Possible effect modiﬁcation by pre-existing cardiovascular disease and cardiovascular risk factors was assessed.
RESULTS: Patients prescribed sibutramine (N= 23 927) appeared to have an elevated rate of myocardial infarction or
cerebrovascular events compared with those taking orlistat (N= 77 047; hazard ratio 1.69, 95% conﬁdence interval 1.12–2.56).
However, subgroup analysis showed the elevated rate was larger in those with pre-existing cardiovascular disease (hazard ratio
4.37, 95% conﬁdence interval 2.21–8.64), compared with those with no cardiovascular disease (hazard ratio 1.52, 95% conﬁdence
interval 0.92–2.48, P-interaction = 0.0076). All-cause mortality was not increased in those prescribed sibutramine (hazard ratio 0.67,
95% conﬁdence interval 0.34–1.32).
CONCLUSIONS: Sibutramine was associated with increased rates of acute cardiovascular events in people with pre-existing
cardiovascular disease, but there was a low absolute risk in those without. Sibutramine’s marketing authorization may have,
therefore, been inappropriately withdrawn for people without cardiovascular disease.
International Journal of Obesity (2015) 39, 1359–1364; doi:10.1038/ijo.2015.86
INTRODUCTION
Before 2010 sibutramine and orlistat were the two European
Union approved pharmaceutical options for weight loss treatment
for individuals with a body mass index (BMI) over 27 kgm2.1 In
January 2010, sibutramine was suspended following a review by
the European Medicines Agency, who found an ‘increased risk of
non-fatal myocardial infarction (MI) and stroke, which outweighed
the possible beneﬁts of medication through weight loss’.2 The
United States Food and Drugs Administration followed suit later
that year. Although concerns about sibutramine’s safety had been
raised before, the risk was clariﬁed by the Sibutramine Cardiovas-
cular Outcomes Trial (SCOUT),3 a randomized, placebo-controlled
trial of over 10 000 patients with increased risk of cardiovascular
events (that is, individuals with pre-existing cardiovascular disease
or with type 2 diabetes mellitus (T2D) and cardiovascular risk
factors). The aim of SCOUT was to clarify the cardiovascular and
cerebrovascular side effect proﬁle of sibutramine. The primary
outcome was a composite of non-fatal MI, non-fatal cerebro-
vascular event (CVE), resuscitation after cardiac arrest, and
cardiovascular death.3 The rate was increased by 16% in the
sibutramine group compared with placebo (hazard ratio (HR) 1.16,
95% conﬁdence interval (CI) 1.03–1.31, P= 0.02), with overall
incidences of 11.4% and 10.0%, in the two groups, respectively.
This increased rate was made up of non-fatal events, rather than
cardiovascular deaths.3
A number of limitations of this trial, especially related to its
generalizability, have been identiﬁed: the increased risk was only
shown in the groups with pre-existing cardiovascular disease,
this was already a contraindication in prescribing guidance;1 all
patients were aged over 55 years; the trial showed only a small
increase in rates, especially when compared with other factors
such as smoking; in certain groups (young women for example), a
statistically signiﬁcant increase in rate ratio may be unimportant in
absolute terms;4 individuals who achieved modest weight loss
associated with the 6-week sibutramine run-in period in SCOUT
had reduced 5-year MI and CVE rates;5 prescribing of sibutramine
in the trial did not reﬂect ‘real World’ use, it continued for ﬁve
times the licensed duration of treatment and the dose was not
modiﬁed if the patient failed to lose weight;4,6–8 there is little
evidence that the alternative weight loss medication (orlistat)
reduces cardiovascular risk,4 so a head-to-head comparison of
these medications may be more informative.
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Given the increasing levels of obesity worldwide, a better
understanding of the ‘real World’ effects of weight loss medica-
tions is needed. Between ﬁrst licensing and suspension, a large
number of patients in the United Kingdom were prescribed
sibutramine, and use of data routinely gathered on these patients
could address some of the limitations of SCOUT, while putting no
further patients at risk. Thus, in this study, we aimed to assess the
comparative risk of sibutramine and orlistat in ‘real World’ use.
Analysis of this cohort has shown that there is unlikely to be a
clinically meaningful difference between these drugs in terms of
weight loss; patients prescribed orlistat lost an average of 0.94 kg
per month (95% CI 0.93–0.95) and patients prescribed sibutramine
lost 1.28 kg per month (95% CI 1.26–1.30) over the ﬁrst 4 months,
but orlistat was slightly superior at sustaining weight loss at 3 years.9
Objectives of the study were to determine the rate of incident
MI or CVE (both fatal and non-fatal) in patients prescribed
sibutramine or orlistat, the rate of MI or CVE in high-risk patients
(that is, those with pre-existing cardiovascular disease or T2D plus
another cardiac risk factor) and the rate of all-cause mortality.
SUBJECTS AND METHODS
Study design
A cohort study using prospectively collected routine primary care data
from the UK Clinical Practice Research Datalink (CPRD).
Data source
CPRD contains anonymized healthcare records for ~ 14 million patients
registered at over 660 general practice (GP) surgeries in the United
Kingdom.10 This represents nearly 10% of the UK population.11 The
database began in 1987 and continuously records information relating to
each consultation. It contains sociodemographic data, prescribed medica-
tion records and Read Codes (searchable clinical terms) relating to
diagnoses (made in primary and secondary care), signs and symptoms, and
procedures and clinical investigations.12–14 CPRD has been shown to be
largely representative of the United Kingdom in terms of GP surgery size
and geographical distribution. Individuals registered in the database are
representative in terms of age and sex.15
Study participants
The cohort was drawn from CPRD starting from the date which the GP data
was deﬁned as being of suitable research quality16 and ending at the start
of June 2013. Patients were included if they: were aged over 18 years old,
were prescribed either sibutramine or orlistat, were recorded as having BMI
⩾ 27 kgm− 2 (in line with NICE guidance for prescribing weight loss
medication), had at least 12 months registration before their ﬁrst
prescription (to identify incident rather than prevalent users) and the
data quality in their record had met minimum agreed standards for use in
research.16 A subgroup analysis was completed on patients that before
their ﬁrst prescription of weight loss medication had a Read code
consistent with a history of cardiovascular disease (not including acute MI
or CVE) such as coronary artery disease, transient ischemic attack, or
peripheral arterial occlusive disease, or T2D with at least one other
cardiovascular risk factor (hypertension, dyslipidaemia, current smoking or
diabetic nephropathy).
Exposures, outcomes and covariates
Patients were deﬁned as exposed during the time they received their ﬁrst
continuous period of sibutramine prescribing; from the date of the ﬁrst
prescription to the date of the last prescription, plus the prescription
length (expected end of treatment date), plus 60 days (to account for
possible delayed side effects of treatment). The comparison group were
patients prescribed orlistat, with the exposure period deﬁned in the same
manner. Patients were censored at the earliest of: event date, death date,
bariatric surgery date or end of ﬁrst constant prescribing period.
The decision to deﬁne patients as exposed 60 days following ﬁnal dose
of sibutramine was made because the postulated mechanism for causing
MI or CVE is via acute changes in heart rate, blood pressure and QT
interval.17 This approach should, therefore, produce an overestimate of the
risk of sibutramine.
The primary outcome of interest was time to ﬁrst MI or CVE (MI/CVE). If a
patient had multiple codes representing acute MI or CVE on multiple dates
in their record the event was recorded as occurring on the date of ﬁrst
entry of that code. A secondary outcome was all-cause mortality; death
was ascertained from patients’ medical records and the date of death
deﬁned as the earliest of any records indicating that death had occurred.
Other covariates were examined as possible confounders: age, sex, BMI, year
of index prescribing of weight loss drug, smoking status, alcohol consumption,
comorbidities (history of coronary heart disease, cerebrovascular disease (CVD),
peripheral vascular disease, any other atheroma, T2D and hypertension) and
co-prescribing (oral anti-glycaemic medication, insulin and statin).
BMI, comorbidities and co-prescribing information was taken from the
most proximate entry in the notes before the start of weight loss medication
prescribing. Smoking and alcohol history were from the most proximate
entry either before or after the start of prescribing. Patients with missing
information on smoking and/or alcohol consumption were compared with
those with complete data. A complete case analysis was performed as we
found no evidence that missingness was associated with the outcome.18
Sample size
Assuming a baseline 7% annual event rate,3 a two-sided type I error rate of
0.05, and power set at 90%, to detect a 10% difference in HR between
orlistat and sibutramine would require a sample size of 19 000 patients
prescribed sibutramine and 58 000 patients prescribed orlistat (with a 1:3
exposed to unexposed ratio). A preliminary analysis revealed 23 927
(23.70%) were exposed to sibutramine and 77 047 to orlistat. Given these
numbers and the predicted number of events, there should be ample
power to explore the main hypothesis.
Statistical analysis
A multivariable Cox model was constructed to assess the association
between sibutramine and both outcomes (MI/CVE, all-cause mortality)
controlled for all other covariates considered, and adjusted for clustering
within GP surgeries. Wald tests were used to calculate P-values for
multivariable models. These results were compared with a propensity
score (PS) analysis. A PS is a measure of the probability that a patient will
receive a particular treatment and is calculated from the observed risk
factors for the outcome and for receiving the treatment.19 This approach is,
therefore, one possible solution to the problem of confounding by
indication in observational studies. Covariates were included in the PS if
they did not introduce multicollinearity in the logistic regression model
predicting treatment allocation. The PS was included in a Cox regression
model as a continuous variable.
Subgroup analysis
Two subgroups were deﬁned a priori based on the analysis of SCOUT;
patients with pre-existing cardiovascular disease (7761 individuals) and
patients with T2D plus at least one other cardiovascular risk factor (that is,
hypertension, statin use and current smoking) (15 455 individuals). Effect
modiﬁcation because of possible interaction between sibutramine
prescribing and existing cardiovascular disease or T2D plus other cardiac
risk factors was examined using the PS-adjusted model.
If there were differences between subgroups these were presented as
number needed to harm. Number needed to harm was calculated from the
estimated survivor function generated from the PS-adjusted Cox regres-
sion model.20
Model checking and sensitivity analysis
Assumption of proportional hazards was checked by producing Aalen plots
and testing whether HRs varied over different intervals of time. A number
of sensitivity analyses were completed (1) PS 1:1 matching, rather than
using the score directly in the regression model; (2) censoring all patients
prescribed orlistat at the date of sibutramine withdrawal (2010); and (3)
assuming that the possible delayed effects of sibutramine lasted 15 days
after the ﬁnal dose, rather than 60 days. All analysis was carried out using
Stata version 13.21
Ethical approval
Ethical approval for this study was obtained from the London School of
Hygiene and Tropical Medicine Ethics Committee and scientiﬁc approval
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was gained from the Independent Scientiﬁc Advisory Committee for
Medicines and Healthcare products Regulatory Agency.
RESULTS
Patient characteristics
In total, 100 974 individuals were included in the analysis, 23 927
(23.70%) were exposed to sibutramine and 77 047 to orlistat.
Median age was 46.09 years (interquartile range (IQR) 36.42–56.66)
median BMI was 36.36 kgm−2 (IQR 32.83–40.91). Patients prescribed
sibutramine were more likely to be female (82 vs 76%), to take the
medication for less time (0.39 vs 0.47 years) and not have
cardiovascular risk factors (Table 1).
Rate of incident MI or CVE
There were 254 incident MI/CVEs in the cohort; 34 in 0.126 per
100 000 person-years at risk (105 PYAR) in patients exposed to
sibutramine and 220 in 1.092 per 105 PYAR in the orlistat group. In
those exposed to sibutramine, the rate of MI/CVE was 269.39.12
per 105 PYAR (95% CI 194.39–384.68). This was not different from
those unexposed (crude HR 1.19, 95% CI 0.80–1.76, P= 0.39).
The fully adjusted model accounting for age, sex, BMI,
smoking status, alcohol use, cardiovascular disease, T2D and
hypertension, as well as clustering by GP surgery gave a HR of 1.65
(95% CI 1.08–2.51, P= 0.018). The PSs were similar for both
sibutramine (median 0.26, IQR 0.22–0.28) and orlistat groups
(median 0.24, IQR 0.20–0.28; Appendix 1). The model adjusting for
PS showed a similar HR to the fully adjusted model (HR 1.69,
95% CI 1.13–2.54, P= 0.011; Table 2). There was evidence that the
effect was stronger in people with concurrent cardiovascular
disease (HR 4.37, 95% CI 2.2–8.64) than those without (HR 1.52,
95% CI 0.92–2.48, P-interaction = 0.0076). There was no evidence
that the effect differed by T2D plus one other cardiac risk factor
(that is, hypertension, statin use and current smoking) status
(Table 2, Figure 1).
In patients with cardiovascular disease prescribed sibutramine,
the number needed to harm (NNH) at 4 months (close to the
median exposure time for sibutramine) was 129 (95% CI 57–360)
and at 1 year was 28 (95% CI 12–77; Table 3).
PS matching on a 1:1 nearest neighbor basis (0.01 caliper),
dropped 53 120 patient-treatment periods that were not matched,
and only included 80 events. This method gave a HR of 1.63 (95%
CI 0.91–2.92, P= 0.10). Although the point estimate was similar,
this method markedly reduced power and was not an efﬁcient use
of the available data. The same was true for censoring all patients
prescribed orlistat at the end of 2010, when sibutramine use was
suspended; HR 1.49 (95% CI 0.98–2.26).
Reducing the exposure period from 60 days following, the ﬁnal
medication dose to 15 days following the ﬁnal dose produced a
PS-adjusted HR of 1.87 (95% CI 1.23–12.84, P= 0.03). The analysis
for interaction between sibutramine and cardiovascular risk
factors produced similar ﬁndings to the original analysis. There
was weak evidence that those without cardiovascular disease had
an elevated rate of MI/CVE if prescribed sibutramine (HR 1.62, 95%
CI 0.98–2.67, P= 0.058), whereas there was strong evidence that
those with pre-existing disease were at increased risk (HR 4.96,
(% CI 2.51–9.78, P= 0.001).
Rate of all-cause mortality
There were 152 deaths in the cohort during the exposure time
(124.82 per 105 PYAR, 95% CI 106.47–146.32). In the sibutramine
exposed group, there were 10 deaths in 0.13 per 105 PAYR
compared with 142 in 1.09 per 105 in the orlistat group. Crude HR
was 0.50 (95% CI 0.26–0.99) This potential difference in mortality
Table 1. Baseline characteristics by prescribing of sibutramine or orlistat
Sibutramine Orlistat P-valuea
Total, N (%) 23 927 (23.70) 77 047 (76.30)
Follow-up time, years—median (IQR) 0.39 (0.24–0.63) 0.47 (0.16–1.68) o0.001
Age at drug start, years—median (IQR) 43.44 (35.10–53.69) 47.00 (36.97–57.46) o0.001
BMI at drug start, kg m− 2—median (IQR) 36.52 (32.87–41.26) 36.33 (32.82–40.82) 0.001
N (%) N (%) P-valueb
Women 19709 (82.38) 58 458 (75.87) o0.001
Cardiovascular disease history 759 (3.17) 4631 (6.01) o0.001
Cerebrovascular disease history 304 (1.27) 1869 (2.43) o0.001
Preexisting peripheral vascular disease 182 (0.76) 1025 (1.33) o0.001
Other atheroma 4 (0.02) 39 (0.05) 0.026
Preexisting Type 2 diabetes mellitus 4130 (17.26) 14 667 (19.03) o0.001
History of hypertension 5337 (22.30) 24 543 (31.85) o0.001
Prescribed
Oral anti-diabetic medication 2922 (12.21) 10 083 (13.08) o0.001
Insulin 894 (3.74) 3131 (4.06) 0.024
Statin 3870 (16.17) 17 757 (23.04) o0.001
Smoking
Never smoked 9997 (41.77) 32 213 (41.80) 0.90
Ex-smoker 8891 (37.25) 28 704 (37.15)
Current smoker 5046 (21.08) 16 142 (20.95)
Alcohol consumption
Non-drinker 4066 (16.99) 13 237 (17.18) o0.001
Ex-drinker 1328 (5.55) 5079 (6.59)
Rare (o2 units per day) 5891(24.61) 19 101 (24.79)
Moderate (3–6 units per day) 10 946 (45.73) 32 906 (42.70)
Heavy (46 units per day) 1703 (7.12) 6736 (7.40)
Abbreviation: IQR, interquartile range. aFrom quantile regression. bFrom χ2-test.
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between sibutramine and orlistat patients was reduced following
adjustment for age, sex, BMI, smoking, alcohol, coronary heart
disease, CVD, peripheral vascular disease, T2D, other atheroma and
hypertension, (HR 0.64, 95% CI 0.32–1.28). Similar results were seen
with PS adjustment (Table 4). There was no clear evidence
of increased rate of all-cause mortality in the group of patients
taking sibutramine who had pre-existing cardiovascular or CVD (HR
1.82, 95% CI 0.53–6.21, P= 0.34). However, there was an increased
rate of mortality in those with T2D and cardiac risk factors (HR 2.72,
95% CI 1.12–6.59–1.57, P=0.026). However, these analyses were
underpowered and relate to death from a wide range of causes
including many that sibutramine would not be expected to
inﬂuence and should, therefore, be viewed as exploratory.
DISCUSSION
This large cohort study, which is representative of ‘real World’
overweight and obese individuals registered with a GP in the
United Kingdom,22 shows that sibutramine is associated with
increased rate of MI/CVE. This increase is primarily driven by
elevated rates in those with pre-existing cardiovascular disease
(even though this group represented only 5% of the cohort), and
those without pre-existing disease may have little or no increased
risk. It also shows that sibutramine is unlikely to alter all-cause
mortality overall, but there remains a possibility of an increased
risk of mortality in a subgroup of people with diabetes and
cardiovascular risk factors. Although limited by the non-random
allocation of sibutramine or orlistat to patients, these ﬁndings are
similar to SCOUT.3
Our group has previously shown the amount of weight loss
associated with sibutramine use is marginal at best9 and in the
context of a poor expected beneﬁt, substantial potential harms
are not tolerable. Our results conﬁrm that the risk beneﬁt balance
in people with existing cardiovascular disease was negative but
our ﬁndings in those without cardiovascular disease are less clear.
We found no strong evidence of an increased risk of MI/CVE in this
group but were unable to rule out a potential doubling of risk due
to small patient numbers. Nonetheless, even if a causal effect
exists in people without CVD, the absolute risk would remain low
in this group.
Strengths and limitations
The use of contemporaneous, representative medical records
avoided the risk of potential biases relating to selection.
Table 2. Hazard ratios for incident MI/CVE from Cox regression
N patients 105 PYAR N events Hazard ratio (95% CI) P-valuea Heterogeneity
Primary analysis
Multivariable adjustedb
Orlistat 77 047 1.092 220 1 0.018
Sibutramine 23 927 0.126 34 1.65 (1.08–2.51)
PSc adjusted
Orlistat 77 047 1.092 220 1 0.013
Sibutramine 23 927 0.126 34 1.69 (1.12–2.56)
Stratiﬁed analyses
Cardiovascular disease
Orlistat 6638 0.104 90 1 o0.00 P= 0.0076
Sibutramine 1123 0.006 12 4.37 (2.21–8.64) 01
No cardiovascular disease
Orlistat 70 409 0.988 130 1 0.103
Sibutramine 22 804 0.120 22 1.52 (0.92–2.48)
Type 2 diabetes +1 cardiovascular risk factor
Orlistat 12 346 0.176 95 1 0.005 P= 0.53
Sibutramine 3109 0.018 9 2.81 (1.37–5.77)
No type 2 diabetes
Orlistat 64 701 0.916 125 1 0.002
Sibutramine 20 818 0.108 25 2.18 (1.35–3.53)
aFrom Wald test. bAdjusted for age; sex; BMI; smoking status; alcohol use; history of: cardiovascular disease, cerebrovascular disease, peripheral vascular
disease, other atheroma, type 2 diabetes and hypertension. cPropensity score.
Figure 1. Interaction between sibutramine and history of cardiovas-
cular disease.
Table 3. Number needed to harm with sibutramine by cardiovascular
disease risk group
NNHa (95% CI) at
4 months
NNHa (95% CI) at
12 months
Cardiovascular disease 129 (57–360) 28 (12–77)
No cardiovascular disease 4809 (1690 to
protective effect)
1749 (615 to
protective effect)
aNumber needed to harm, from estimated survivor function following Cox
regression with PS adjustment.
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Information bias should partially have been avoided by the use of
prescribing data as exposure, in the UK GPs are responsible for all
ongoing prescribing, which is detailed and well recorded in
CPRD.13
The similarities between orlsitat and sibutramine treatment
groups in terms of PS suggested that confounding by indication
was unlikely to be a major issue in this study. Two important
differences could be history of CVD and prescribing of statins.
Indeed, people in the sibutramine group were less likely to have
pre-existing CVD, and less likely to receive statins than those
receiving orlistat. This is in keeping with the prescribing guidance
for these drugs. Although we adjusted for this in our analyses, it is
possible that residual confounding remained. However, this would
tend to lead to an underestimate of the increased risk among
sibutramine users. It is also possible that our PS model could have
been improved by inclusion of extra baseline characteristics such
as blood pressure, heart rate and lipid proﬁle but this analysis was
not possible, and we instead adjusted for correlates of these
characteristics such as diagnosis of hypertension, prescribing of
statins and a range of other cardiovascular health factors.
The study design reveals a temporal relationship between
sibutramine exposure and MI/CVE, this relationship is strong in the
pre-existing cardiovascular disease group, and a plausible and
coherent causal mechanism for this effect has been identiﬁed.8
Exposure was deﬁned as starting at the time of prescription
issue and ending 60 days after the calculated end date of the ﬁnal
prescription. Poor adherence to prescribed drug regimens is a
problem with all medication, and this is particularly true if side
effects are unpleasant, as can be the case with sibutramine and
orlistat.23 It is, therefore, likely that exposure time has been
overestimated, which could lead to a result biased towards no
effect. However, in the sibutramine exposed group the median
period of usage was 0.38 years, suggesting that patients did re-
present to their GP to collect further prescriptions. Also, the
sensitivity analysis reducing the at risk period after the ﬁnal
medication date to 15 days found a similar increased rate in those
exposed to sibutramine.
Although hard outcomes such as MI, CVE or death should be
well recorded by GPs there is some evidence that CPRD
underestimates the rate of these events by as much as 25%.24
Despite this there is no reason to assume events are differentially
recorded for those individuals exposed to sibutramine, and so this
may have resulted in reduced power, rather than incorrect
estimates of effect. As well as this there may be errors in identifying
acute events. Often a patient would have multiple codes
representing acute MI or CVE on multiple dates in their record.
When this occurred their full note history was searched for a
suggestion that they had experienced a previous event, if so they
were excluded. If there was no evidence of a previous event, the MI
or CVE was recorded as occurring on the date of ﬁrst entry of that
code. However, this may be inaccurate if the patients had an event
before the start of study follow-up, had recently moved practices or
their event was coded late (from a hospital letter for instance).
Conclusions and recommendations
Sibutramine, as used in routine clinical practice, was associated with
an increased risk of acute cardiovascular and CVEs in patients with
underlying cardiovascular disease. The absolute risk appears to be
high in this group, conﬁrming that the contraindications deﬁned in
sibutramine’s licensing were important and appropriate.1 However,
the lack of a clear increased risk in people without underlying
cardiovascular disease and the overall low absolute rate of events in
this group suggest it may have remained a suitable treatment
option for patients with no history of cardiovascular disease.
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Table 4. Hazard ratios for all-cause mortality from Cox regression
N patients 105 PYAR N events Hazard ratio (95% CI) P-valuea Heterogeneity
Primary analysis
Multivariable adjustedb
Orlistat 77 047 1.092 142 1 0.212
Sibutramine 23 927 0.126 10 0.64 (0.32–1.28)
PSc adjusted
Orlistat 77 047 1.092 142 1 0.243
Sibutramine 23 927 0.126 10 0.67 (0.34–1.32)
Stratiﬁed analyses
Cardiovascular disease
Orlistat 6638 0.104 46 1 0.338 P= 0.11
Sibutramine 1123 0.006 3 1.82 (0.26–1.29)
No cardiovascular disease
Orlistat 70 409 0.988 96 1 0.184
Sibutramine 22 804 0.120 7 0.58 (0.26–1.29)
Type 2 diabetes +1 cardiovascular risk factor
Orlistat 12 346 0.176 65 1 0.026 P= 0.0074
Sibutramine 3109 0.018 6 2.72 (1.12–6.59)
No type 2 diabetes
Orlistat 64 701 0.916 77 1 0.147
Sibutramine 20 818 0.108 4 0.47 (0.17–1.31)
aFrom Wald test. bAdjusted for age; sex; BMI; smoking status; alcohol use; history of: cardiovascular disease, cerebrovascular disease, peripheral vascular
disease, other atheroma, type 2 diabetes and hypertension. cPropensity score.
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